Skip to content

The Impact of Pulmonary-Specific Formulated Nutritional Supplements on the Quality of Body Composition in Patients After Lung Transplantation

The Impact of Pulmonary-Specific Formulated Nutritional Supplements on the Quality of Body Composition in Patients After Lung Transplantation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119798
Enrollment
Unknown
Registered
2026-03-03
Start date
2026-03-03
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative recovery phase after lung transplantation (stable post-transplant patients)

Interventions

Interention group:Oral administration of pulmonary-specific nutritional supplement (Langeli Complex Nutrient), once daily, for 3 consecutive months
Control group:Oral administration of traditional nutritional supplement (Reneng), once daily, for 3 consecutive months

Sponsors

Department of rehabilitation medicine, China Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years old, who are recipients of the first unilateral or bilateral lung transplantation and in stable condition after surgery. 2. At the time of discharge, the nutritional assessment by the nutrition department indicates insufficient oral intake, requiring enteral nutrition support. 3. Patients are willing to cooperate with rehabilitation and nutritional assessment during the perioperative period. 4. Having normal cognitive function, being able to cooperate with understanding the research content and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Mental and cognitive diseases or other conditions that prevent cooperation with nutrition management and rehabilitation. 2. Complications such as severe infection, malignant tumor, and liver and kidney failure. 3. Postoperative severe complications (such as severe graft-versus-host disease) or requiring re-mechanical ventilation. 4. Unable to cooperate with follow-up or unable to obtain informed consent from the patient or their family members.

Design outcomes

Primary

MeasureTime frame
Change in 6-Minute Walk Test (6MWT) Distance;

Secondary

MeasureTime frame
Change in Lean Body Mass;Change in Short Physical Performance Battery (SPPB) Score;Change in 36-Item Short Form Health Survey (SF-36) Score;Change in Skeletal Muscle Index;Change in Grip Strength;

Countries

China

Contacts

Public ContactWang Siyuan

Department of rehabilitation medicine, China Japan Friendship Hospital

wsyzmx@sina.com+86 186 1033 5283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026